HUTCHMED Reports the NDA Submission of Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
- The NDA was based on the results from the P-III multi-regional clinical trial (FRESCO-2) in the US, EU, Japan, and Australia, as well as results from the P-III (FRESCO) trial conducted in China evaluating fruquintinib + BSC vs PBO + BSC
- Both trials met their 1EPs & 2EPs i.e., the therapy showed a significant and clinical improvement in OS and PFS. The therapy was also found to be well tolerated while the results from the global registrational (FRESCO-2) clinical trial were published in The Lancet
- Fruquintinib is a selective oral inhibitor of VEGFR -1, -2, and -3 which was developed and marketed in China by HUTCHMED, under the brand name Elunate
Ref: HUTCHMED | Image: HUTCHMED
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.